Skip to content

Evaluation of the Ambu® AuraGain in Ambulatory Surgery

Analysis of 150 Consecutive Uses of the Ambu® AuraGain Supraglottic Airway by One Anaesthetist in Ambulatory Surgery

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04501068
Enrollment
150
Registered
2020-08-06
Start date
2018-01-01
Completion date
2020-06-01
Last updated
2020-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Airway

Keywords

Ambu® AuraGainTM, Second Generation Laryngeal Masks Airway

Brief summary

The study was designed to evaluate the success rate, time of insertion, sealing efficacy and security of the Ambu® AuraGain in patients undergoing ambulatory surgery by one anesthetist

Detailed description

Supraglottic devices (SGD), in all their different forms, have become an authentic innovation in airway management especially in day surgery. The Ambu® AuraGainTM (Ambu A/S, Ballerup, Denmark) is a new single-use, anatomically curved supraglottic airway with an integrated gastric access port designed to provide functional separation of the respiratory and digestive tracts allowing the exit of gastric contents and the passage of a gastric tube to manage gastric contents. Its characteristics in the design, composition by a smooth and atraumatic material, the presence of the gastric drainage access, with potential improved patient safety and its characteristic of being disposable, suggests a significant expansion of its use in the coming years. The series in the literature reporting performance or safety of use of the Ambu® AuraGainTM come from studies on selected cases and in certain surgical procedures. However, there are limited studies that have evaluated the efficacy of the device in routine clinical practice in patients intervened in ambulatory surgery and performed by a single investigator.

Interventions

DEVICEAmbu® AuraGainTM

Evaluate the time of insertion, performance, security and insertion success rate of the Ambu® AuraGainTM in patients undergoing ambulatory surgery and general anaesthesia

Sponsors

Hospital General Universitario Gregorio Marañon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients undergoing surgery procedures in ambulatory surgery usually performed with supraglottic devices. * ASA physical status I-III patients * Age 18-no limit

Exclusion criteria

* Patients with known difficult airway * Patients with increased risk of aspiration * Patient refusal to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
Evaluate the number of attempts to insert the Ambu® AuraGainTM supraglottic airwayThe number of insertion attempts will be collected after anesthesia inductionInsertion attempts (in numbers) From picking up the Ambu® AuraGainTM supraglottic airway until the mask is placed into the patient mouth. (in numbers)
Evaluate the time to insert the Ambu® AuraGainTM supraglottic airwayThe insertion time will be collected after anesthesia induction after administration of propofolThe time from picking up the Ambu® AuraGainTM supraglottic airway until the cuff was inflated. (in seconds)

Secondary

MeasureTime frameDescription
Blood pressure during insertion of the Ambu® AuraGainTM supraglottic airwayAt baseline and every 3 minutes until 6 minutes after insertion of the Ambu® AuraGainTM supraglottic airwayBlood pressure in mmHg
Heart rate during insertion of the Ambu® AuraGainTM supraglottic airway heart rateAt baseline and every 3 minutes until 6 minutes after insertion of the Ambu® AuraGainTM supraglottic airway]Heart rate in beep per minute
BIS dataAt baseline and every 3 minutes until 6 minutes after insertion of the Ambu® AuraGainTM supraglottic airway (To evaluate the evolution of BIS values during insertion of the Ambu® AuraGainTM supraglottic airwayBis data: number from 100 (awake) to 40-45 (anesthetic status)
Oropharyngeal leak pressure of the Ambu® AuraGainTM supraglottic airway.The Oropharyngeal leak pressure of the Ambu® AuraGainTM supraglottic airway will be collected 10 minutes after the Ambu® AuraGainTM supraglottic airway will be inserted]The Oropharyngeal leak pressure of the Ambu® AuraGainTM supraglottic airway will be determined with an intracuff pressure of 60 cm H2O by closing the expiratory valve of the breathing circle circuit at a fixed gas flow of 3 L/min and noting the pressure at which an oropharyngeal leak occurs. (in cm H2O)

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026